Ernexa Therapeutics filings document a Delaware biotechnology issuer developing synthetic allogeneic iMSC cell therapies and reporting as a public company with common stock and common stock purchase warrants listed on Nasdaq. Registration statements and amendments disclose the company's cellular-therapy business, operating and financial results, capital structure, risk factors, clinical and regulatory development disclosures, and offering-related security terms.
Current reports on Form 8-K cover material events including amendments to the certificate of incorporation for a 1-for-25 reverse stock split, Nasdaq minimum-bid compliance notices, Regulation FD investor-presentation materials, changes in the independent registered public accounting firm, going-concern explanatory disclosures and internal-control matters.
Ernexa Therapeutics Inc. reported a $12.5 million net loss and $9.6 million of operating cash use for the nine months ended September 30, 2026. Its September 30 cash balance was $5.6 million, below the amount needed for its current operating plan and forecast cash needs for the next 12 months; management expects ATM access to cover a significant portion of the shortfall and is pursuing financing. For the same nine-month period, research and development expense was $6.578 million, versus $3.480 million a year earlier, primarily reflecting ERNA-101 study and manufacturing costs.
An independent preclinical ovarian-cancer mouse study found complete tumor clearance and long-term survival in 10 of 15 models (67%) treated with ERNA-101 plus PD-1 blockade; neither treatment alone produced complete clearance or durable survival. Ernexa is prioritizing ERNA-101 and has deprioritized ERNA-201 for near-term resources.
ATM sales generated approximately $3.7 million net as of September 30, 2026; on October 6, 2026, an additional 43,700 shares generated $0.1 million net. Nasdaq restored bid-price compliance on May 29, 2026. A mandatory panel monitor continues through May 5, 2027, and a bid-price deficiency during monitoring would trigger a delisting determination.
Freebird Partners LP reports beneficial ownership of 119,015 shares of Ernexa Therapeutics Inc. (ERNA) common stock, equal to 7.0% of the class. Its general partner, Freebird Investments LLC, and the partnership’s sole member, Curtis W. Huff, may also be deemed to share that ownership. The reported amount includes 52,000 common shares and 67,015 shares issuable upon warrant exercise. The warrants cannot be exercised to the extent that an exercise would result in beneficial ownership of more than 9.99% of outstanding common stock.
Ernexa Therapeutics Inc. made an investor presentation available on October 15, 2026, and said it would also be available on its website that day. The company says it uses its website to distribute important information, including press releases, investor presentations and financial information, and may use it for time-critical information before or instead of a press release or SEC filing. The presentation’s forward-looking statements disclosure is incorporated by reference into the announcement.
Ernexa Therapeutics Inc. (ERNA) has a new initial insider ownership report. Director Robert J. Spiegel filed a Form 3 as a reporting person of the company. The filing lists no reportable transactions, derivative positions, or equity holdings for him as of the reporting date.
Ernexa Therapeutics Inc. (ERNA) reported that on September 16, 2026 it made a corporate fact sheet and an investor presentation available to investors, furnished as Exhibits 99.1 and 99.2 to this report under a Regulation FD disclosure.
The company states that these materials, including their “Forward-Looking Statements” disclosure, are incorporated by reference into this Item 7.01 and will also be accessible on its investor relations website starting September 17, 2026. Ernexa explains that it uses its website as a regular channel to distribute important and time‑critical company information, while clarifying that the furnished materials are not deemed filed for purposes of Section 18 of the Exchange Act.
Ernexa Therapeutics Inc. (ERNA) reports that its board of directors has appointed Robert J. Spiegel, M.D. as a director, effective September 14, 2026. He will serve until a successor is duly elected and qualified or until earlier death, resignation, or removal.
Dr. Spiegel will be compensated under Ernexa’s Board of Directors Compensation Plan that became effective August 15, 2026 and is described in the company’s Form 10-Q for the quarter ended June 30, 2026. The company states there are no appointment-related arrangements, no family relationships with current leadership, and no related-party transactions with Dr. Spiegel that are reportable under Item 404(a) of Regulation S-K.
Ernexa Therapeutics Inc. (ERNA) reported that director James Arthur Bristol received two grants of stock options to purchase common stock. On 2026-08-31, he was granted 8,320 options with a $4.57 exercise price, expiring on 2036-08-31, vesting one-third on the first anniversary and the remainder in 24 monthly installments, subject to continued service. He was also granted 5,083 options at a $4.57 exercise price, expiring on 2036-08-31, in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, with 100% vesting on December 31, 2026, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Peter Cicala received two grants of stock options on August 31, 2026. One grant covers 5,943 options with an exercise price of $4.57 per share, vesting one-third on the first anniversary and the rest in 24 monthly installments, expiring August 31, 2036. A second grant covers 5,083 options at $4.57 per share, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vesting 100% on December 31, 2026, also expiring August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.
Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock. The options have an exercise price of $4.57 per share and expire on August 31, 2036. Following this grant, Wexler holds 5,943 stock options directly. Vesting is time-based: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.